Aquestive Therapeutics, Inc. (NASDAQ:AQST) Receives $10.14 Average Price Target from Brokerages

Shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST) have been given an average recommendation of “Buy” by the seven ratings firms that are presently covering the company, MarketBeat Ratings reports. Seven research analysts have rated the stock with a buy recommendation. The average 12-month price objective among brokerages that have updated their coverage on the stock in the last year is $10.14.

AQST has been the topic of several research analyst reports. Alliance Global Partners reaffirmed a “buy” rating on shares of Aquestive Therapeutics in a research note on Friday, March 7th. HC Wainwright reaffirmed a “buy” rating and set a $10.00 target price on shares of Aquestive Therapeutics in a research note on Tuesday. Oppenheimer assumed coverage on Aquestive Therapeutics in a report on Monday, June 2nd. They issued an “outperform” rating and a $7.00 price objective on the stock. Raymond James Financial set a $7.00 price objective on Aquestive Therapeutics in a report on Friday, March 7th. Finally, Lake Street Capital dropped their price objective on Aquestive Therapeutics from $10.00 to $8.00 and set a “buy” rating on the stock in a report on Friday, March 7th.

Aquestive Therapeutics Price Performance

NASDAQ:AQST opened at $3.40 on Friday. Aquestive Therapeutics has a fifty-two week low of $2.12 and a fifty-two week high of $5.80. The stock’s 50-day moving average is $2.82 and its two-hundred day moving average is $3.06. The stock has a market cap of $337.72 million, a PE ratio of -5.76 and a beta of 1.94.

Aquestive Therapeutics (NASDAQ:AQST) last released its earnings results on Monday, May 12th. The company reported ($0.24) earnings per share for the quarter, missing the consensus estimate of ($0.17) by ($0.07). The business had revenue of $8.72 million during the quarter, compared to the consensus estimate of $12.23 million. On average, equities research analysts anticipate that Aquestive Therapeutics will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Aquestive Therapeutics

Large investors have recently added to or reduced their stakes in the stock. Summit Wealth & Retirement Planning Inc. bought a new stake in Aquestive Therapeutics during the first quarter worth approximately $29,000. Victory Capital Management Inc. bought a new stake in Aquestive Therapeutics during the first quarter worth approximately $31,000. Cambridge Investment Research Advisors Inc. bought a new stake in Aquestive Therapeutics during the first quarter worth approximately $33,000. New York State Common Retirement Fund boosted its position in Aquestive Therapeutics by 713.3% during the fourth quarter. New York State Common Retirement Fund now owns 12,200 shares of the company’s stock worth $43,000 after purchasing an additional 10,700 shares during the period. Finally, Dynamic Technology Lab Private Ltd bought a new stake in Aquestive Therapeutics during the fourth quarter worth approximately $44,000. Institutional investors own 32.45% of the company’s stock.

Aquestive Therapeutics Company Profile

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.